Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth

Leventogiannis, Konstantinos; Gkolfakis, Paraskevas; Spithakis, Georgios; Tsatali, Aikaterini; Pistiki, Aikaterini; Sioulas, Athanasios D.; Giamarellos‐Bourboulis, Evangelos J.; Triantafyllou, Konstantinos

doi:10.1007/s12602-018-9401-3

Cited by 37 publications

(28 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 9 However, an open-label, prospective study published in 2018 demonstrated that 30-day treatment with a commercially available probiotic significantly improved bowel function satisfaction in patients with IBS-D (n=11) compared with patients with non-IBS-D (n=15) on days 30 and 60 ( p =0.05 and 0.04, respectively). 47 Further, following 30-day probiotic treatment, patients with IBS and concomitant SIBO experienced a significantly greater decrease from baseline in the severity of IBS symptoms compared with patients with IBS without SIBO at day 60 (71.3% vs 10.6%, respectively; p =0.02). 47 Given the potential benefit in targeting the gut microbiota, a nonsystemic antibiotic has been investigated to prevent the need for long-term daily therapy and minimize possible AEs.…”

Section: Role Of Gut Microbiota In Ibsmentioning

confidence: 85%

“… 47 Further, following 30-day probiotic treatment, patients with IBS and concomitant SIBO experienced a significantly greater decrease from baseline in the severity of IBS symptoms compared with patients with IBS without SIBO at day 60 (71.3% vs 10.6%, respectively; p =0.02). 47 Given the potential benefit in targeting the gut microbiota, a nonsystemic antibiotic has been investigated to prevent the need for long-term daily therapy and minimize possible AEs.…”

Section: Role Of Gut Microbiota In Ibsmentioning

confidence: 85%

See 1 more Smart Citation

Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin

Chang¹

2018

CEG

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a common gastrointestinal (GI) disorder characterized by abdominal pain that occurs with defecation or alterations in bowel habits. Further classification is based on the predominant bowel habit: constipation-predominant IBS, diarrhea-predominant IBS (IBS-D), or mixed IBS. The pathogenesis of IBS is unclear and is considered multifactorial in nature. GI dysbiosis, thought to play a role in IBS pathophysiology, has been observed in patients with IBS. Alterations in the gut microbiota are observed in patients with small intestinal bacterial overgrowth, and overgrowth may occur in a subset of patients with IBS. The management of IBS includes therapies targeting the putative factors involved in the pathogenesis of the condition. However, many of these interventions (eg, eluxadoline and alosetron) require long-term, daily administration and have important safety considerations. Agents thought to modulate the gut microbiota (eg, antibiotics and probiotics) have shown potential benefits in clinical studies. However, conventional antibiotics (eg, neomycin) are associated with several adverse events and/or the risk of bacterial antibiotic resistance, and probiotics lack uniformity in composition and consistency of response in patients. Rifaximin, a nonsystemic antibiotic administered as a 2-week course of therapy, has been shown to be safe and efficacious for the treatment of IBS-D. Rifaximin exhibits a favorable benefit-to-harm ratio when compared with daily therapies for IBS-D (eg, alosetron and tricyclic antidepressants), and rifaximin was not associated with the emergence of bacterial antibiotic resistance. Thus, short-course therapy with rifaximin is an appropriate treatment option for IBS-D.

show abstract

Section: Role Of Gut Microbiota In Ibsmentioning

confidence: 85%

Section: Role Of Gut Microbiota In Ibsmentioning

confidence: 85%

Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin

Chang¹

2018

CEG

View full text Add to dashboard Cite

show abstract

“…But, well-designed RCTs are needed to substantiate these findings and to establish the optimal regimen [ 28 , 29 ]. A recent prospective study demonstrated that superior clinical efficacy of four probiotics (Saccharomyces boulardii, Bifidobacterium lactis, Lactobacillus acidophilus, and Lactobacillus plantarum) in patients with IBS and SIBO [ 30 ]. However, in a randomized trial that enrolled patients treated with Saccharomyces boulardii and placebo, an overall improvement of the quality of life was detected in the Saccharomyces boulardii group.…”

Section: Discussionmentioning

confidence: 99%

Effect of Combined Live Probiotics Alleviating the Gastrointestinal Symptoms of Functional Bowel Disorders

Shi

Gao

Zhang

2020

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Objective. Changes of the gut microbiota are related to the pathogenesis of functional bowel disorders (FBDs), and probiotic supplementation may be an effective treatment option. Therefore, we aimed to investigate the effect of combined live probiotics on the gastrointestinal symptoms of FBDs via altering the gut microbiota. Methods. Patients with the gastrointestinal symptoms of FBDs attending the Outpatient Department, from July to November 2019, were recruited. After the bowel preparation with polyethylene glycol electrolyte powder and colonoscopy, patients with normal result of colonoscopy were randomly divided into the probiotics group and control group. Patients in the probiotics group were prescribed with combined live Bacillus subtilis and Enterococcus faecium enteric-coated capsules for 4 weeks. Small intestinal bacteria overgrowth (SIBO) was measured by lactulose hydrogen breath test, and the microbial DNA was extracted from the fecal samples and the bacteria were classified by 16S rDNA gene amplicon sequencing. Results. Twenty-five patients of each group were recruited, and there was no significant difference between the probiotics and control groups on baseline gastrointestinal symptom rating scale (GSRS), positive rate of SIBO, and relative abundances of the gut microbiota at the phylum level. After 4 weeks of treatment, the values of the probiotics and control groups were as follows: GSRS 1.4±1.4 and 3.6±1.6 and positive rate of SIBO 28.0% and 56.0%, respectively. The median relative abundances of the gut microbiota were 1.01% and 5.03% Actinobacteria and 43.80% and 35.17% Bacteroidetes at the phylum level; 0.76% and 3.29% Bifidobacterium, 0.13% and 0.89% Cillinsella, 0.03% and 0.01% Enterococcus, 0.18% and 0.36% Lachnospiraceae, 0.10% and 0.16% Ruminococcus torques group, 1.31% and 2.44% Blautia, and 0.83% and 2.02% Fusicatenibacter at the genus level (P<0.05), respectively. Conclusion. Combined live probiotic supplementation after the bowel preparation can alter the gut microbiota, decontaminate SIBO, and alleviate the gastrointestinal symptoms of FBDs. This trial is registered with ChiCTR1900026472.

show abstract

“…Similarly, a multi-strain probiotic containing S. boulardii, B. lactis, L. acidophilus, and L. plantarum alleviated the signs of constipation, diarrhea, and modulates the microbial community in the small intestine of IBS patients [ 91 ]. The evidence of the existing relationship between alteration in the intestinal microbiome and cognitive behavioral changes is also increasing the application of probiotics [ 92 ].…”

Section: Applications and Biological Functions Of Multi-strain Probioticsmentioning

confidence: 99%

Multi-Strain Probiotics: Synergy among Isolates Enhances Biological Activities

Kwoji

Aiyegoro

Okpeku

et al. 2021

Biology

View full text Add to dashboard Cite

The use of probiotics for health benefits is becoming popular because of the quest for safer products with protective and therapeutic effects against diseases and infectious agents. The emergence and spread of antimicrobial resistance among pathogens had prompted restrictions over the non-therapeutic use of antibiotics for prophylaxis and growth promotion, especially in animal husbandry. While single-strain probiotics are beneficial to health, multi-strain probiotics might be more helpful because of synergy and additive effects among the individual isolates. This article documents the mechanisms by which multi-strain probiotics exert their effects in managing infectious and non-infectious diseases, inhibiting antibiotic-resistant pathogens and health improvement. The administration of multi-strain probiotics was revealed to effectively alleviate bowel tract conditions, such as irritable bowel syndrome, inhibition of pathogens and modulation of the immune system and gut microbiota. Finally, while most of the current research focuses on comparing the effects of multi-strain and single-strain probiotics, there is a dearth of information on the molecular mechanisms of synergy among multi-strain probiotics isolates. This forms a basis for future research in the development of multi-strain probiotics for enhanced health benefits.

show abstract

Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth

Cited by 37 publications

References 22 publications

Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin

Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin

Effect of Combined Live Probiotics Alleviating the Gastrointestinal Symptoms of Functional Bowel Disorders

Multi-Strain Probiotics: Synergy among Isolates Enhances Biological Activities

Contact Info

Product

Resources

About